drugset / Trial / NCT06751485
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN003 versus investigator's choice of chemotherapy in patients with platinum-resistant, relapsed epithelial Ovarian, primary peritoneal, or fallopian tube cancer.
Timeline
- Start
- 2025-01-15
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Doxorubicin | Other / unclassified | — | — |
| Subject | JSKN003 | Monoclonal antibody | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Topotecan | Small molecule | — | — |